AR056346A1 - Compuestos y composiciones como inhibidores de quinasa de proteina - Google Patents
Compuestos y composiciones como inhibidores de quinasa de proteinaInfo
- Publication number
- AR056346A1 AR056346A1 ARP060101900A ARP060101900A AR056346A1 AR 056346 A1 AR056346 A1 AR 056346A1 AR P060101900 A ARP060101900 A AR P060101900A AR P060101900 A ARP060101900 A AR P060101900A AR 056346 A1 AR056346 A1 AR 056346A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- 4alkyl
- hetero
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 abstract 1
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 abstract 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 abstract 1
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 abstract 1
- 101150036586 FES gene Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 abstract 1
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 abstract 1
- 101000987310 Homo sapiens Serine/threonine-protein kinase PAK 2 Proteins 0.000 abstract 1
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 abstract 1
- 101150003567 Mapk12 gene Proteins 0.000 abstract 1
- 101150060694 Mapk13 gene Proteins 0.000 abstract 1
- 102000056243 Mitogen-activated protein kinase 12 Human genes 0.000 abstract 1
- 108700015929 Mitogen-activated protein kinase 12 Proteins 0.000 abstract 1
- 102000056248 Mitogen-activated protein kinase 13 Human genes 0.000 abstract 1
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 abstract 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 abstract 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 abstract 1
- 101150056950 Ntrk2 gene Proteins 0.000 abstract 1
- 101100202399 Oryza sativa subsp. japonica SAPK4 gene Proteins 0.000 abstract 1
- 101150071831 RPS6KA1 gene Proteins 0.000 abstract 1
- 101150105578 SAPK3 gene Proteins 0.000 abstract 1
- 102100027939 Serine/threonine-protein kinase PAK 2 Human genes 0.000 abstract 1
- 102100030070 Serine/threonine-protein kinase Sgk1 Human genes 0.000 abstract 1
- 101150110875 Syk gene Proteins 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos, composiciones farmacéuticas que comprenden a estos compuestos, y uso de los compuestos para preparar un medicamento. Los compuesto son utiles para prevenir o tratar las enfermedades o los trastornos asociados con una actividad de quinasa anormal o mal regulada, en particular las enfermedades o los trastornos que involucren una activacion anormal de las quinasas Abl, Bcr-Abl, Bmx, BTK, b-RAF, c RAF, CSK, cSRC, Fes, FGFR3, Flt3, IKKalfa, IKKbeta, JNK1alfa1, JNK2alfa2, Lck, Met, MKK4, MKK6, p70S6K, PAK2, PDGFRalfa, PKA, PKCalfa, PKD2, ROCK-II, Ros, Rsk1, SAPK2alfa, SAPK2beta, SAPK3, SAPK4, SGK, Syk, Tie2 y TrkB. Estas enfermedades incluyen trastornos proliferativos y enfermedades de una activacion inadecuada de los sistemas inmune y nervioso. Reivindicacion 1: Un compuesto seleccionado a partir de la formula (1), n se selecciona a partir de 0, 1 y 2; m se selecciona a partir de 0, 1 y 2; Y1 se selecciona a partir de N y CR5; en donde R5 se selecciona a partir de hidrogeno y alquilo C1-6; Y2 se selecciona a partir de O y S; R1 se selecciona a partir de hidrogeno y alquilo C1-6; R2 se selecciona a partir de hidrogeno y alquilo C1-6; R3 se selecciona a partir de hidrogeno, halogeno, hidroxilo, alquilo C1-6, alcoxilo C1-6, alquilo C1-6 sustituido por halogeno, y alcoxilo C1-6 sustituido por halogeno; R4 se selecciona a partir de-NR5C(O)R6 y -C(O)NR5R6; en donde R5 se selecciona a partir de hidrogeno y alquilo C1-6; en donde R6 se selecciona a partir de ariloC6-10-alquiloC0-4, heteroariloC5-10-alquiloC0-4, ciclo-alquiloC3-10-alquiloC0-4, y hetero-cicloalquiloC3-10-alquiloC0-4; en donde cualquier arilo, hetero-arilo, ciclo-alquilo, o hetero-ciclo-alquilo, o hetero-ciclo-alquilo de R6 está opcionalmente sustituido con 1 a 3 radicales seleccionados a partir de halogeno, hidroxilo, -NR5R5, alquilo C1-6, alcoxilo C1-6, alquilo C1-6 sustituido por halogeno, alcoxilo C1-6 sustituido por halogeno, hetero-ariloC5-10-alquiloC1-4, heterocicloC3-8-alquiloC0-4 y heterocicloC3-8-alcoxiloC0-4; en donde cualquier sustituyente de hetero-arilo o hetero-ciclo-alquilo R6 está opcionalmente sustituido por 1 a 3 radicales independientemente seleccionados a partir de alquilo C1-6 e hidroxilo-alquiloC1-6; R7 se selecciona a partir de hidrogeno, halogeno, hidroxilo, alquilo C1-6, alcoxilo C1-6, alquilo C1-6 sustituido por halogeno, alcoxilo C1-6 sustituido halogeno, ariloC6-10-alquiloC0-4, hetero-ariloC5-10-alquiloC0-4, cicloalquiloC3-10-alquiloC0-4, y hetero-ciclo-alquiloC3-10-alquiloC0-4; y las sales farmacéuticamente aceptables, hidratos, solvatos, e isomeros del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68068405P | 2005-05-13 | 2005-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056346A1 true AR056346A1 (es) | 2007-10-03 |
Family
ID=37074687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101900A AR056346A1 (es) | 2005-05-13 | 2006-05-11 | Compuestos y composiciones como inhibidores de quinasa de proteina |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8183248B2 (es) |
| EP (1) | EP1891066B1 (es) |
| JP (1) | JP5016593B2 (es) |
| KR (1) | KR20080025039A (es) |
| CN (1) | CN101175753B (es) |
| AR (1) | AR056346A1 (es) |
| AT (1) | ATE492545T1 (es) |
| AU (1) | AU2006247757B2 (es) |
| BR (1) | BRPI0610278A2 (es) |
| CA (1) | CA2607299C (es) |
| DE (1) | DE602006019088D1 (es) |
| ES (1) | ES2358344T3 (es) |
| GT (1) | GT200600197A (es) |
| MX (1) | MX2007014066A (es) |
| PE (1) | PE20061366A1 (es) |
| PL (1) | PL1891066T3 (es) |
| RU (1) | RU2411242C2 (es) |
| TW (1) | TW200726766A (es) |
| WO (1) | WO2006124462A2 (es) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080075837A (ko) | 2005-10-28 | 2008-08-19 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
| EA018573B1 (ru) | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| SG10201508035TA (en) * | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
| EP2070929A1 (en) | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| CN102149712A (zh) * | 2008-02-29 | 2011-08-10 | 阵列生物制药公司 | 吡唑并[3，4-b]吡啶Raf抑制剂 |
| ES2392482T3 (es) * | 2008-02-29 | 2012-12-11 | Array Biopharma, Inc. | Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF |
| CN102015707A (zh) * | 2008-02-29 | 2011-04-13 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| WO2009111280A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| PT2300013T (pt) | 2008-05-21 | 2017-10-31 | Ariad Pharma Inc | Derivados de fósforo como inibidores de cinases |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| JP5369183B2 (ja) | 2008-07-16 | 2013-12-18 | ファーマサイクリックス，インク． | 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤 |
| WO2011109593A1 (en) * | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Substituted-5-aminopyrrolo/pyrazolopyridines |
| US20120087915A1 (en) | 2010-06-03 | 2012-04-12 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| BR112014000314A2 (pt) | 2011-07-08 | 2017-01-10 | Novartis Ag | derivados de pirrolo pirimidina |
| CA2841080A1 (en) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| CN103073508B (zh) * | 2011-10-25 | 2016-06-01 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
| US9782406B2 (en) | 2011-10-25 | 2017-10-10 | Peking University Shenzhen Graduate School | Kinase inhibitor and method for treatment of related diseases |
| JP2015504876A (ja) * | 2011-12-22 | 2015-02-16 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | セリン／トレオニンキナーゼ阻害剤としての２，４−ジアミン−ピリミジン誘導体 |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| MX348290B (es) | 2012-06-04 | 2017-06-05 | Pharmacyclics Llc | Formas cristalinas de un inhibidor de tirosina quinasa de bruton. |
| CN107652289B (zh) | 2012-06-13 | 2020-07-21 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
| MX2015001081A (es) | 2012-07-24 | 2015-10-14 | Pharmacyclics Inc | Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk). |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| MA38183A1 (fr) | 2012-11-15 | 2017-03-31 | Pharmacyclics Inc | Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| JP6449244B2 (ja) | 2013-04-19 | 2019-01-09 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｆｇｆｒ抑制剤としての二環式複素環 |
| WO2015017812A1 (en) | 2013-08-02 | 2015-02-05 | Pharmacyclics, Inc. | Methods for the treatment of solid tumors |
| CA2920534A1 (en) | 2013-08-12 | 2015-02-19 | Pharmacyclics Llc | Methods for the treatment of her2 amplified cancer |
| CN105764896A (zh) | 2013-09-30 | 2016-07-13 | 药品循环有限责任公司 | 布鲁顿氏酪氨酸激酶的抑制剂 |
| US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
| WO2016019233A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| AU2015300798A1 (en) | 2014-08-07 | 2017-02-02 | Pharmacyclics Llc | Novel formulations of a Bruton's tyrosine kinase inhibitor |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| CN105801584B (zh) * | 2016-03-16 | 2019-03-05 | 中国药科大学 | 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN119241541A (zh) | 2018-05-04 | 2025-01-03 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| CN109374896A (zh) * | 2018-11-22 | 2019-02-22 | 中山大学孙逸仙纪念医院 | Plk3前列腺癌预后诊断检测试剂及其试剂盒 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| IL293001A (en) | 2019-12-04 | 2022-07-01 | Incyte Corp | Derivatives of fgfr repressors |
| CA3164650A1 (en) | 2019-12-13 | 2021-06-17 | Nippon Shinyaku Co., Ltd. | Compound and composition as pdgf receptor kinase inhibitor |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| AU3951899A (en) | 1998-06-19 | 2000-01-05 | Pfizer Products Inc. | Pyrrolo(2,3-d)pyrimidine compounds |
| ATE380031T1 (de) | 1999-12-10 | 2007-12-15 | Pfizer Prod Inc | Pyrrolo 2,3-d pyrimidinderivate enthaltende zusammensetzungen |
| CA2412560C (en) | 2000-06-26 | 2008-12-30 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents |
| JP2007502776A (ja) * | 2003-08-15 | 2007-02-15 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｒｔｋ阻害剤としての６−置換アニリノプリン類 |
| US7338957B2 (en) * | 2003-08-28 | 2008-03-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
-
2006
- 2006-05-10 CN CN2006800161327A patent/CN101175753B/zh not_active Expired - Fee Related
- 2006-05-10 BR BRPI0610278-6A patent/BRPI0610278A2/pt not_active IP Right Cessation
- 2006-05-10 CA CA2607299A patent/CA2607299C/en not_active Expired - Fee Related
- 2006-05-10 PL PL06752481T patent/PL1891066T3/pl unknown
- 2006-05-10 RU RU2007145935/04A patent/RU2411242C2/ru not_active IP Right Cessation
- 2006-05-10 ES ES06752481T patent/ES2358344T3/es active Active
- 2006-05-10 KR KR1020077026230A patent/KR20080025039A/ko not_active Ceased
- 2006-05-10 MX MX2007014066A patent/MX2007014066A/es active IP Right Grant
- 2006-05-10 US US11/914,308 patent/US8183248B2/en not_active Expired - Fee Related
- 2006-05-10 GT GT200600197A patent/GT200600197A/es unknown
- 2006-05-10 WO PCT/US2006/018096 patent/WO2006124462A2/en not_active Ceased
- 2006-05-10 EP EP06752481A patent/EP1891066B1/en not_active Not-in-force
- 2006-05-10 DE DE602006019088T patent/DE602006019088D1/de active Active
- 2006-05-10 JP JP2008511323A patent/JP5016593B2/ja not_active Expired - Fee Related
- 2006-05-10 AU AU2006247757A patent/AU2006247757B2/en not_active Ceased
- 2006-05-10 AT AT06752481T patent/ATE492545T1/de active
- 2006-05-11 AR ARP060101900A patent/AR056346A1/es unknown
- 2006-05-11 PE PE2006000501A patent/PE20061366A1/es not_active Application Discontinuation
- 2006-05-12 TW TW095116981A patent/TW200726766A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8183248B2 (en) | 2012-05-22 |
| EP1891066B1 (en) | 2010-12-22 |
| CA2607299C (en) | 2013-05-07 |
| ES2358344T3 (es) | 2011-05-09 |
| JP2008540556A (ja) | 2008-11-20 |
| JP5016593B2 (ja) | 2012-09-05 |
| RU2411242C2 (ru) | 2011-02-10 |
| CN101175753A (zh) | 2008-05-07 |
| PL1891066T3 (pl) | 2011-05-31 |
| DE602006019088D1 (de) | 2011-02-03 |
| WO2006124462A3 (en) | 2007-01-04 |
| GT200600197A (es) | 2007-03-28 |
| CA2607299A1 (en) | 2006-11-23 |
| RU2007145935A (ru) | 2009-06-20 |
| TW200726766A (en) | 2007-07-16 |
| BRPI0610278A2 (pt) | 2010-06-08 |
| MX2007014066A (es) | 2008-02-11 |
| WO2006124462A2 (en) | 2006-11-23 |
| AU2006247757B2 (en) | 2009-08-27 |
| CN101175753B (zh) | 2011-03-23 |
| KR20080025039A (ko) | 2008-03-19 |
| ATE492545T1 (de) | 2011-01-15 |
| EP1891066A2 (en) | 2008-02-27 |
| US20090118273A1 (en) | 2009-05-07 |
| PE20061366A1 (es) | 2007-01-05 |
| AU2006247757A1 (en) | 2006-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056346A1 (es) | Compuestos y composiciones como inhibidores de quinasa de proteina | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| JOP20220247A1 (ar) | مثبطات كرومينون تفارغية لفوسفوينوسيتيد 3 كيناز (pi3k) لعلاج أمراض مرتبطة بتعديل p13k | |
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| AR063343A1 (es) | Compuestos para modular c-kit y receptores de pdgfr | |
| NO20072887L (no) | Forbindelser og sammensetninger som protein kinase inhibitorer | |
| ATE482958T1 (de) | Verbindungen und zusammensetzungen als proteinkinaseinhibitoren | |
| PE20110223A1 (es) | DERIVADOS DE PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN, COMO INHIBIDORES DE QUINASA | |
| EA200901654A1 (ru) | Ингибиторы и способы с их использованием | |
| AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
| AR049511A1 (es) | Compuestos y composiciones como inhibidores de quinasa de proteina | |
| ATE444294T1 (de) | Verbindungen und zusammensetzungen als proteinkinaseinhibitoren | |
| EA201000003A1 (ru) | Ингибиторы протеинкиназ и способы их применения | |
| UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| MX2023000812A (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| AR098534A1 (es) | Terapias para tratar trastornos mieloproliferativos | |
| UY31821A (es) | Compuestos y composiciones como inhibidores de quinasa | |
| NO20075641L (no) | Kroman og kromenderivater og ders anvendelse | |
| AR066214A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas | |
| ECSP077998A (es) | Moduladores de cinasa de aminoquinolina y aminoquinazolina | |
| GT200600394A (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis. | |
| ECSP077994A (es) | Aminopirimidinas como moduladores de cinasa | |
| NI201000145A (es) | DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET. | |
| ECSP077991A (es) | Aminopirimidinas como moduladores de cinasa | |
| NO20080967L (no) | Benzimidazoler nyttige som inhibitorer av proteinkinaser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |